Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Current Assets (2016 - 2025)

Historic Current Assets for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $2.0 million.

  • Pharma's Current Assets fell 5284.71% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 5284.71%. This contributed to the annual value of $2.9 million for FY2025, which is 2183.54% down from last year.
  • As of Q3 2025, Pharma's Current Assets stood at $2.0 million, which was down 5284.71% from $2.2 million recorded in Q2 2025.
  • Pharma's 5-year Current Assets high stood at $23.5 million for Q1 2021, and its period low was $2.0 million during Q3 2025.
  • In the last 5 years, Pharma's Current Assets had a median value of $6.1 million in 2023 and averaged $9.4 million.
  • As far as peak fluctuations go, Pharma's Current Assets soared by 6843.53% in 2021, and later crashed by 6169.55% in 2023.
  • Over the past 5 years, Pharma's Current Assets (Quarter) stood at $19.2 million in 2021, then plummeted by 51.37% to $9.4 million in 2022, then tumbled by 61.7% to $3.6 million in 2023, then dropped by 14.85% to $3.1 million in 2024, then plummeted by 34.32% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.2 million for Q2 2025, and $2.9 million during Q1 2025.